Cancer Therapy Brings Hope to Autoimmune Disease Patients

Jan Janisch-Hanzlik couldn't carry her grandchildren anymore without fear of falling, and her multiple sclerosis was pushing her toward needing a wheelchair full-time. But the 49-year-old nurse refused to give up, calling a research clinic every other month until she could become the first patient in a groundbreaking trial.

The treatment she received, called CAR T cell therapy, was originally designed to fight blood cancers by reprogramming immune cells to hunt down diseased cells. Now doctors are using that same approach to help people with autoimmune diseases, where the body's defenses mistakenly attack healthy tissue.

Since the FDA approved the first CAR T cancer treatment in 2017, researchers have wondered if it could reset immune systems gone wrong. German doctors first tested it on a lupus patient in 2021 with remarkable results. Today, hundreds of clinical trials are testing CAR T for multiple sclerosis, lupus, Graves' disease, and other conditions.

The science is surprisingly straightforward. Doctors remove a patient's T cells, reprogram them to target problematic B cells that create harmful antibodies, and return them to the body. These enhanced cells then eliminate the source of autoimmune attacks.

Results from recent trials have stunned medical professionals. In a December 2025 study of 26 people with stiff person syndrome, a rare condition causing muscle stiffness and painful spasms, most patients walked faster within 16 weeks. Eight people who relied on walkers and canes could walk short distances unassisted. By April, all 26 patients had stopped using other immune therapies.

"I think it's a game changer," says Dr. Amanda Piquet, who led the stiff person syndrome study at the University of Colorado. Before treatment, many participants moved with slow, mechanical gaits and couldn't imagine life without assistance.

The treatment comes with risks. Early cancer patients experienced dangerous inflammation as their reprogrammed cells attacked targets. Patients spend a week under close monitoring after receiving CAR T therapy. The long-term effects and durability of benefits remain uncertain.

The Ripple Effect

For Janisch-Hanzlik, the decision to try experimental treatment wasn't just about her own health. Multiple sclerosis has a genetic component, meaning her two young grandchildren face elevated risk of developing the disease. She wanted to pioneer a path that might spare them and countless others from the same struggle.

Her courage is helping researchers understand how to safely adapt cancer treatments for autoimmune conditions. Each patient in these trials contributes data that brings doctors closer to FDA approval and wider access.

The early success of autoimmune CAR T therapy represents a fundamental shift in how medicine approaches diseases where the body attacks itself. Instead of managing symptoms with daily medications that suppress the entire immune system, doctors may soon reset it with a single treatment.

Janisch-Hanzlik went into her treatment on June 9, 2025, with a mix of hope and fear, but she knew the potential payoff was worth it.